Tvardi's TTI-109 Phase 1 Data Shows Bioequivalence, Improved Tolerability; Plans for New Indications
TVRD sits 37% above its 52-week low of $1.5.
Summary
Tvardi Therapeutics announced positive Phase 1 data for its STAT3 inhibitor TTI-109, demonstrating bioequivalence to TTI-101 with significantly improved gastrointestinal tolerability. The drug also showed evidence of STAT3 target engagement. This follows an 8-K filing earlier today disclosing the same results. For a micro-cap company that recently reported a going concern warning and filed for a $200 million mixed shelf offering, these positive clinical results are critical for attracting future funding and advancing its pipeline. The company plans to advance TTI-109 into new dermatologic and GI indications, pending IND clearance and additional capital.
At the time of this announcement, TVRD was trading at $2.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $1.50 to $43.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.